We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
+40.93%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.34B
AUM Growth
+$414M
Cap. Flow
+$90.9M
Cap. Flow %
6.77%
Top 10 Hldgs %
72.61%
Holding
36
New
5
Increased
7
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
MBX
MBX Biosciences
MBX
+$26.7M
2
UTHR icon
United Therapeutics
UTHR
+$22.7M
3
APLS
Apellis Pharmaceuticals
APLS
+$18.9M
4
PHVS icon
Pharvaris
PHVS
+$15M
5
VERA icon
Vera Therapeutics
VERA
+$13.9M

Top Sells

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$13.2M
2
TVTX icon
Travere Therapeutics
TVTX
+$11.1M
3
COGT icon
Cogent Biosciences
COGT
+$7.18M
4
URGN icon
UroGen Pharma
URGN
+$6.72M
5
LQDA icon
Liquidia Corp
LQDA
+$2.49M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DSGN icon
26
Design Therapeutics
DSGN
$736M
$7.75M 0.58%
1,029,579
– –
KALV
27
DELISTED
KalVista Pharmaceuticals
KALV
$7.38M 0.55%
+606,171
New +$8.38M
IRWD icon
28
Ironwood Pharmaceuticals
IRWD
$611M
$7.16M 0.53%
5,466,825
– –
CRBU icon
29
Caribou Biosciences
CRBU
$156M
$7.15M 0.53%
3,067,774
– –
URGN icon
30
UroGen Pharma
URGN
$2B
$6.94M 0.52%
282,412
-374,161
-57% -$6.72M
GERN icon
31
Geron
GERN
$911M
$4.74M 0.35%
3,456,318
– –
STRO icon
32
Sutro Biopharma
STRO
$379M
$4.42M 0.33%
508,810
– –
EWTX icon
33
Edgewise Therapeutics
EWTX
$4.39B
$4.12M 0.31%
253,979
– –
PRQR icon
34
ProQR Therapeutics
PRQR
$243M
$3.51M 0.26%
1,649,462
– –
CLYM
35
Climb Bio
CLYM
$735M
$2.07M 0.15%
1,028,341
– –
LQDA icon
36
Liquidia Corp
LQDA
$7.67B
– –
-200,047
Closed -$2.49M
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Kynam Capital Management held 36 positions worth $1.34B, up 45% from $929M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Kynam Capital Management deployed $90.9M of net new capital in Q3 2025, opening 5 new positions and adding to 7 existing holdings. Its largest new stake was MBX Biosciences: 2,000,000 shares worth $35M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was CG Oncology, an estimated $13.2M trimmed.

  • Kynam Capital Management's largest Q3 2025 buy was MBX Biosciences: 2,000,000 shares worth $35M.
  • Kynam Capital Management added most to Vera Therapeutics in Q3 2025, an estimated $13.9M increase.
  • Kynam Capital Management's biggest Q3 2025 reduction was CG Oncology, cutting an estimated $13.2M.
  • Kynam Capital Management fully exited Liquidia Corp in Q3 2025, selling an estimated $2.49M.
  • Kynam Capital Management's ten largest holdings make up 73% of its $1.34B portfolio in Q3 2025.
  • Kynam Capital Management opened 5 new positions and closed 1 in Q3 2025.
  • Kynam Capital Management's portfolio value rose 45% quarter-over-quarter to $1.34B.

Based on Kynam Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.